Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

NICE has received three appeals against the Final Appraisal Determination on the above technology from the following organisations:

• Pfizer Limited
• Leukaemia CARE
• Jointly appealing: Royal College of Pathologists, Royal College of Physicians and the Association of Cancer Physicians

The appeal panel will convene on Friday 3 November 2017 at NICE, Level 1a, City Tower, Piccadilly Plaza, Manchester M1 4BT to hear oral representations from the appellant.

This page was last updated: 03 November 2017